NCT04037254 2026-04-06
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NRG Oncology
OHSU Knight Cancer Institute
Nanobiotix
University of Texas Southwestern Medical Center
AHS Cancer Control Alberta
Mayo Clinic